NCT05345717

Novel Desensitization Kidney Transplantation

Novel Desensitization Protocol With Proteasome Inhibitor and Costimulation Blockade for Highly Sensitized Patients to Allow for Successful Kidney Transplantation. A Pilot Study.

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This proposal's objective is to determine whether belatacept, in conjunction with a proteasome inhibitor can be used to safely increase the likelihood of finding an acceptable donor for highly HLA sensitized kidney transplant candidates.

Detailed description

This is a pilot study to test the safety and effectiveness of the desensitization therapy with belatacept and proteasome inhibitor to increase the likelihood of of finding an acceptable donor for highly HLA sensitized kidney transplant candidates.

Conditions

• Kidney Transplantation
• End Stage Kidney Disease (ESRD)

Interventions

Type	Name	Description
DRUG	Belatacept Injection	Patient will initiate belatacept therapy and will received 2 cycles of proteasome inhibitor therapy

Timeline

• Start date: 2022-05-01
• Primary completion: 2025-09-12
• Completion: 2025-09-12
• First posted: 2022-04-26
• Last updated: 2025-12-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study